

REMARKS


Amendments

Claim 1 is amended in an effort to address the pending rejections. All other claims are canceled. These amendments introduce no new matter.

The foregoing amendments to the Specification address the formal objections to grammar, etc. The usage of "KIX" remains unchanged because KIX is a well-established term of art for a binding domain originally characterized as a phosphoserine binding domain in the coactivator CREB-binding protein (CBP). The name KIX is not an acronym per se, but appears to be a play on a CREB domain called KID (for kinase-inducible domain) Parker et al., Mol Cell Biol. 1996 Feb;16(2):694-703 (attached).

The Examiner is invited to call the undersigned with any suggestions for amending the claims or further clarifying any of the foregoing. We petition for and authorize charging our Deposit Account No.19-0750 all necessary extensions of time. The Commissioner is authorized to charge any fees or credit any overcharges relating to this communication to our Dep. Acct. No.19-0750 (order UTSD:1510-1).

Respectfully submitted,
Science & Technology Law Group


Richard Aron Osman, J.D., Ph.D., Reg. No. 36,627
Tel (949) 218-1757; Fax (949) 218-1767

"To Help Our Customers Get Patents"
Mission Statement, USPTO External Customer Services Guide